logologo
CtrlK
logologo

Home

Watchlist

Market Screener

By Industry
Top Performing
Top Trading

Portfolio

News

News Feed
SEC Filings

Strategy Lab

Hedgefund
Community

Stocks

/

MYGN

Myriad Genetics Inc

MYGN

NASDAQ

Biotechnology

$5.88

USD

+$0.45 (+8.29%)

Last close

Market Cap:

$527.02M

Volume:

5.2M

Price (USD)
Key Statistics

Previous Close

$5.43

Day Range

$5.34 - $5.90

52 Week Range

$3.53 - $8.59

Average Volume (10 Days)

1.5M

P/E Ratio

0.00

Dividend Yield

0.00%

About This Company

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

CEO

Mr. Samraat Raha

Headquaters

Salt Lake City, UTAH, US

Founded

1995

Employees

2,700

Similar Stocks

MNPR

Monopar Therapeutics Inc

$87.68

+0.1%

ALT

Altimmune Inc

$2.82

-1.7%

STTK

Shattuck Labs Inc

$6.44

+9.0%

PROK

Prokidney Corp

$1.83

+7.7%

RGNX

Regenxbio Inc

$10.48

+2.3%

ASMB

Assembly Biosciences Inc

$26.74

+10.2%

MDXG

MiMedx Group Inc

$3.93

+3.1%

BBOT

BridgeBio Oncology Therapeutics Inc

$7.40

-3.8%

TRAX

First Tracks Biotherapeutics Inc

$16.03

-2.1%